Happy Holidays and Happy New Year from all of us at Lunai Bioworks and BioSymetrics. Want to learn more about what we build and why we build it? Check out our websites at www.lunaibioworks.com and www.biosymetrics.com.
LUNAI
Harnessing phenomics and AI to turn disease signals into new therapies. We uncover treatments by reading disease in motion, decoded by AI, confirmed in living systems, built for patients.
www.lunaibioworks.com
December 24, 2025 at 4:59 PM
Happy Holidays and Happy New Year from all of us at Lunai Bioworks and BioSymetrics. Want to learn more about what we build and why we build it? Check out our websites at www.lunaibioworks.com and www.biosymetrics.com.
We generated the sheet music ourselves, since AI infamously and humorously struggles with valid notation. That mix of creativity and rigor is how we approach drug discovery and biodefense every day.
December 24, 2025 at 4:59 PM
We generated the sheet music ourselves, since AI infamously and humorously struggles with valid notation. That mix of creativity and rigor is how we approach drug discovery and biodefense every day.
Learn more about Lunai Bioworks and BioSymetrics: www.lunaibioworks.com and www.biosymetrics.com.
LUNAI
Harnessing phenomics and AI to turn disease signals into new therapies. We uncover treatments by reading disease in motion, decoded by AI, confirmed in living systems, built for patients.
www.lunaibioworks.com
December 18, 2025 at 5:24 PM
Learn more about Lunai Bioworks and BioSymetrics: www.lunaibioworks.com and www.biosymetrics.com.
Are you exploring partnerships in AI, biomarkers, or neurodegeneration? Let’s connect at JPM and discuss our offerings for target discovery and trial enrichment. Reach out to schedule a meeting in San Francisco.
December 18, 2025 at 5:24 PM
Are you exploring partnerships in AI, biomarkers, or neurodegeneration? Let’s connect at JPM and discuss our offerings for target discovery and trial enrichment. Reach out to schedule a meeting in San Francisco.
In Parkinson’s disease, BioSymetrics is using Augusta to integrate PPMI proteomics with clinical phenotyping. Powered by Contingent AI, this work supports progression-linked subtyping and biomarker-informed trial enrichment.
December 18, 2025 at 5:24 PM
In Parkinson’s disease, BioSymetrics is using Augusta to integrate PPMI proteomics with clinical phenotyping. Powered by Contingent AI, this work supports progression-linked subtyping and biomarker-informed trial enrichment.
In Parkinson’s disease, BioSymetrics is using Augusta to integrate PPMI proteomics with clinical phenotyping. Powered by Contingent AI, this work supports progression-linked subtyping and biomarker-informed trial enrichment.
December 18, 2025 at 5:24 PM
In Parkinson’s disease, BioSymetrics is using Augusta to integrate PPMI proteomics with clinical phenotyping. Powered by Contingent AI, this work supports progression-linked subtyping and biomarker-informed trial enrichment.
Learn more about Lunai Bioworks and BioSymetrics: www.lunaibioworks.com and www.biosymetrics.com.
LUNAI
Harnessing phenomics and AI to turn disease signals into new therapies. We uncover treatments by reading disease in motion, decoded by AI, confirmed in living systems, built for patients.
www.lunaibioworks.com
December 18, 2025 at 5:16 PM
Learn more about Lunai Bioworks and BioSymetrics: www.lunaibioworks.com and www.biosymetrics.com.
Are you exploring partnerships in AI, biomarkers, or neurodegeneration? Let’s connect at JPM and discuss our offerings for target discovery and trial enrichment. Reach out to schedule a meeting in San Francisco.
December 18, 2025 at 5:16 PM
Are you exploring partnerships in AI, biomarkers, or neurodegeneration? Let’s connect at JPM and discuss our offerings for target discovery and trial enrichment. Reach out to schedule a meeting in San Francisco.
DCCT updates include our allogeneic dendritic cell immunotherapy platform, designed as an off-the-shelf approach manufactured from healthy donor cells and stored ready-to-use for high-need solid tumors.
December 18, 2025 at 5:16 PM
DCCT updates include our allogeneic dendritic cell immunotherapy platform, designed as an off-the-shelf approach manufactured from healthy donor cells and stored ready-to-use for high-need solid tumors.
In Parkinson’s disease, BioSymetrics is using Augusta to integrate PPMI proteomics with clinical phenotyping. Powered by Contingent AI, this work supports progression-linked subtyping and biomarker-informed trial enrichment.
December 18, 2025 at 5:16 PM
In Parkinson’s disease, BioSymetrics is using Augusta to integrate PPMI proteomics with clinical phenotyping. Powered by Contingent AI, this work supports progression-linked subtyping and biomarker-informed trial enrichment.
Join Lunai Bioworks at the Biotech Showcase during JPM 2026 in San Francisco (Jan 12-15). Gabe Musso, Chief Scientific Officer at BioSymetrics (a Lunai Bioworks company), will be representing our team. Let’s connect. #JPM #BiotechShowcase #AI
December 18, 2025 at 5:16 PM
Join Lunai Bioworks at the Biotech Showcase during JPM 2026 in San Francisco (Jan 12-15). Gabe Musso, Chief Scientific Officer at BioSymetrics (a Lunai Bioworks company), will be representing our team. Let’s connect. #JPM #BiotechShowcase #AI
Read the full Lunai Bioworks Parkinson's press release here: www.prnewswire.com/news-release...
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market
/PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of...
www.prnewswire.com
December 9, 2025 at 5:42 PM
Read the full Lunai Bioworks Parkinson's press release here: www.prnewswire.com/news-release...
These findings create a foundation for experimental validation, proof-of-concept design, and partnerships to co-develop biomarkers and next-generation Parkinson's therapies. Learn more about our Augusta platform and PD program at www.lunaibioworks.com.
LUNAI
Harnessing phenomics and AI to turn disease signals into new therapies. We uncover treatments by reading disease in motion, decoded by AI, confirmed in living systems, built for patients.
www.lunaibioworks.com
December 9, 2025 at 5:42 PM
These findings create a foundation for experimental validation, proof-of-concept design, and partnerships to co-develop biomarkers and next-generation Parkinson's therapies. Learn more about our Augusta platform and PD program at www.lunaibioworks.com.
These biologically anchored subtypes support inclusion and enrichment criteria, biomarker-ready endpoints, and pathway-level target prioritization that can reduce trial risk, improve signal detection, and help therapies reach patients most likely to benefit as programs advance.
December 9, 2025 at 5:42 PM
These biologically anchored subtypes support inclusion and enrichment criteria, biomarker-ready endpoints, and pathway-level target prioritization that can reduce trial risk, improve signal detection, and help therapies reach patients most likely to benefit as programs advance.
By integrating proteomic data from the PPMI study with clinical phenotyping, we uncovered progression-linked patient groups – from fast motor decline to rapid cognitive worsening to a female-enriched subtype with broad functional impairment.
December 9, 2025 at 5:42 PM
By integrating proteomic data from the PPMI study with clinical phenotyping, we uncovered progression-linked patient groups – from fast motor decline to rapid cognitive worsening to a female-enriched subtype with broad functional impairment.
If you're attending ICMLA, be sure to add the AI Technology panel to your schedule, join the discussion on where AI is headed next in practical, high-impact applications, and visit the ICMLA schedule to learn more: www.icmla-conference.org/icmla25/sche...
December 3, 2025 at 5:20 PM
If you're attending ICMLA, be sure to add the AI Technology panel to your schedule, join the discussion on where AI is headed next in practical, high-impact applications, and visit the ICMLA schedule to learn more: www.icmla-conference.org/icmla25/sche...
Learn more about Lunai Bioworks and our platform: lunaibioworks.com
November 25, 2025 at 7:50 PM
Learn more about Lunai Bioworks and our platform: lunaibioworks.com
Read the full press release for data and details: www.prnewswire.com/news-release...
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models
/PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has secured its first Letter of Intent...
www.prnewswire.com
November 25, 2025 at 7:50 PM
Read the full press release for data and details: www.prnewswire.com/news-release...
This LOI builds on a peer-reviewed publication, a successful pre-IND meeting with the FDA, and collaborations with investigators at UCLA and @ucirvine.bsky.social, as we work to move DCCT into a Phase I trial for patients facing some of the most aggressive solid tumors.
November 25, 2025 at 7:50 PM
This LOI builds on a peer-reviewed publication, a successful pre-IND meeting with the FDA, and collaborations with investigators at UCLA and @ucirvine.bsky.social, as we work to move DCCT into a Phase I trial for patients facing some of the most aggressive solid tumors.
Our DCCT platform is a first-in-class, allogeneic dendritic cell therapy designed to scale. By using healthy donor cells and an off-the-shelf model, we aim to cut manufacturing timelines from weeks to days and expand access for patients with solid tumors.
November 25, 2025 at 7:50 PM
Our DCCT platform is a first-in-class, allogeneic dendritic cell therapy designed to scale. By using healthy donor cells and an off-the-shelf model, we aim to cut manufacturing timelines from weeks to days and expand access for patients with solid tumors.